Literature DB >> 28298956

Phosphorus Regulation in Chronic Kidney Disease.

Wadi N Suki1, Linda W Moore1.   

Abstract

Serum phosphorus levels stay relatively constant through the influence of multiple factors-such as parathyroid hormone, fibroblast growth factor 23, and vitamin D-on the kidney, bone, and digestive system. Whereas normal serum phosphorus ranges between 3 mg/dL to 4.5 mg/dL, large cross-sectional studies have shown that even people with normal kidney function are sometimes found to have levels ranging between 1.6 mg/dL and 6.2 mg/dL. While this may partially be due to diet and the factors mentioned above, total understanding of these atypical ranges of serum phosphorus remains uncertain. Risks for bone disease are high in people aged 50 and older, and this group comprises a large proportion of people who also have chronic kidney disease. Consuming diets low in calcium and high in phosphorus, especially foods with phosphate additives, further exacerbates bone turnover. Existing bone disease increases the risk for high serum phosphorus, and higher serum phosphorus has been associated with increased adverse events and cardiovascular-related mortality both in people with chronic kidney disease and in those with no evidence of disease. Once kidney function has deteriorated to end-stage disease (Stage 5), maintaining normal serum phosphorus requires dietary restrictions, phosphate-binding medications, and dialysis. Even so, normal serum phosphorus remains elusive in many patients with Stage 5 kidney disease, and researchers are testing novel targets that may inhibit intestinal transport of phosphorus to achieve better phosphate control. Protecting and monitoring bone health should also aid in controlling serum phosphorus as kidney disease advances.

Entities:  

Keywords:  chronic kidney disease; glomerular filtration rate; hyperphosphatemia/drug therapy; osteoporosis; phosphates; serum phosphorus; sodium-phosphate cotransporter proteins

Mesh:

Substances:

Year:  2016        PMID: 28298956      PMCID: PMC5347182          DOI: 10.14797/mdcj-12-4s1-6

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  13 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Bone health: preventing osteoporosis.

Authors:  Regina M Benjamin
Journal:  Public Health Rep       Date:  2010 May-Jun       Impact factor: 2.792

3.  Association of dietary phosphate and serum phosphorus concentration by levels of kidney function.

Authors:  Linda W Moore; Joy V Nolte; A Osama Gaber; Wadi N Suki
Journal:  Am J Clin Nutr       Date:  2015-06-03       Impact factor: 7.045

4.  Estimation of total usual calcium and vitamin D intakes in the United States.

Authors:  Regan L Bailey; Kevin W Dodd; Joseph A Goldman; Jaime J Gahche; Johanna T Dwyer; Alanna J Moshfegh; Christopher T Sempos; Mary Frances Picciano
Journal:  J Nutr       Date:  2010-02-24       Impact factor: 4.798

5.  Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.

Authors:  Marcello Tonelli; Frank Sacks; Marc Pfeffer; Zhiwei Gao; Gary Curhan
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

6.  High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females.

Authors:  Virpi E Kemi; Merja U M Kärkkäinen; Christel J E Lamberg-Allardt
Journal:  Br J Nutr       Date:  2006-09       Impact factor: 3.718

7.  Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Ian H de Boer; Tessa C Rue; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2008-11-06       Impact factor: 8.860

8.  Habitual high phosphorus intakes and foods with phosphate additives negatively affect serum parathyroid hormone concentration: a cross-sectional study on healthy premenopausal women.

Authors:  Virpi E Kemi; Hannu J Rita; Merja U M Kärkkäinen; Heli T Viljakainen; Marika M Laaksonen; Terhi A Outila; Christel J E Lamberg-Allardt
Journal:  Public Health Nutr       Date:  2009-02-16       Impact factor: 4.022

9.  Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease.

Authors:  Edward J Weinman; Paul D Light; Wadi N Suki
Journal:  Am J Kidney Dis       Date:  2013-06-12       Impact factor: 8.860

Review 10.  Management of natural and added dietary phosphorus burden in kidney disease.

Authors:  Adamasco Cupisti; Kamyar Kalantar-Zadeh
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

View more
  5 in total

1.  Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

Authors:  Alvin Lee Day; Sarah L Morgan; Kenneth G Saag
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-15       Impact factor: 5.346

2.  DAXX mediates high phosphate-induced endothelial cell apoptosis in vitro through activating ERK signaling.

Authors:  Shu Wang; Mingyu Wu; Ling Qin; Yaxiang Song; Ai Peng
Journal:  PeerJ       Date:  2020-06-19       Impact factor: 2.984

3.  Prediction of 72-hour mortality in patients with extremely high serum C-reactive protein levels using a novel weighted average of risk scores.

Authors:  Kai Saito; Hitoshi Sugawara; Kiyoshi Ichihara; Tamami Watanabe; Akira Ishii; Takahiko Fukuchi
Journal:  PLoS One       Date:  2021-02-19       Impact factor: 3.240

4.  Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial.

Authors:  Kullaya Takkavatakarn; Pongpratch Puapatanakul; Jeerath Phannajit; Warumphon Sukkumme; Pajaree Chariyavilaskul; Patita Sitticharoenchai; Asada Leelahavanichkul; Pisut Katavetin; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Toxins (Basel)       Date:  2021-09-27       Impact factor: 4.546

5.  Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia.

Authors:  Yuan-Yuei Chen; Tung-Wei Kao; Cheng-Wai Chou; Chen-Jung Wu; Hui-Fang Yang; Ching-Huang Lai; Li-Wei Wu; Wei-Liang Chen
Journal:  Sci Rep       Date:  2018-02-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.